Navigation Links
DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
Date:4/3/2013

Horsham, PA (PRWEB) April 03, 2013

The DIA 2013 49th Annual Meeting, to be held June 23–27 at the Boston Convention & Exhibition Center, will feature 22 tracks and more than 250 educational offerings, including sessions addressing urgent issues surrounding patient advocacy, big data and Alzheimer’s. These sessions, along with a large number of panels, forums and networking opportunities, aim to foster collaboration and drive conversation between patients and key industry and regulation professionals to advance the development and regulation of safe and effective medical products.

Sessions include:

Big Data: Impact on Innovation, June 25, 10:15 a.m. - Susan Dentzer, editor-in-chief of the leading peer-reviewed medical journal Health Affairs, will chair this discussion about how data are being used to support safety and efficiency, about how data affect the payer landscape, and to share best practices. Dentzer will be joined by keynote speaker Michael Rosenblatt, chief medical officer of Merck & Co., along with an esteemed panel of experts representing the pharmaceutical industry, regulatory affairs, clinical research and patient perspectives.

Advancing Alzheimer’s Innovation, June 26 - A variety of sessions will focus on advancing care in Alzheimer’s disease, bringing together representatives from the patient advocacy and industry communities.

  • A Call to Action, 10:15 a.m. - Meryl Comer, president of the Geoffrey Beene Foundation, will chair this discussion about the global impact of Alzheimer’s and the progress toward earlier detection, along with key steps being taken to address the growing epidemic.
  • Patient Advocacy, Caregiver Support and Health Care System Impact, 1:45 p.m. - Leaders from Sanofi and the Alliance for Aging Research will discuss how to foster collaboration to bridge the gap between industry and regulators, and enhance clinical trials and data collection.
  • Clinical Development Successes and Challenges, 4:00 p.m. - Top executives from Eisai Inc. and Merck & Co., and leading researchers from Massachusetts Alzheimer’s Disease Research Center, will discuss the challenges encountered in early and late clinical development, lessons learned from past trials and recommendations in trial design.

Patient Advocacy Panel, June 24, 10 a.m. - A panel of current fellows and alumni from the DIA Patient Advocate Fellowship Program will share inspiring stories of advancing patient care through their organizations. Patients and advocates will discuss how organizations can take vital steps to improve development of treatment, such as setting up registries to collect patient data, educating patients on diseases, working hand in hand with clinicians and researchers, identifying and boosting attendance for clinical trials and navigating the pharmaceutical industry and regulation to advance the development of treatment for diseases, especially in cases in which no treatment yet exists.

For more information, visit http://www.diahome.org.

About DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., with offices in Basel, Switzerland; Tokyo; Mumbai, India; and Beijing.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10597344.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
4. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
5. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
7. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
8. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
9. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
10. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
11. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- VWR Corporation (NASDAQ: VWR), the leading global independent provider of ... reported its financial results for the fourth quarter and full ... 4Q16 record quarterly net sales of $1.13 billion, ... 4Q16 EMEA-APAC segment net sales ... Americas net sales increased 2.5%, or down 0.9% on an ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):